Tags

Type your tag names separated by a space and hit enter

Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle.
Histochem Cell Biol. 2010 May; 133(5):557-65.HC

Abstract

Plasma anandamide (AEA) levels fluctuate throughout the menstrual cycle and in early pregnancy in a pattern suggesting its involvement in implantation and early pregnancy maintenance through mechanisms that might involve its binding to cannabinoid receptors CB1 and CB2. Plasma AEA levels are maintained by the actions of the enzymes fatty acid amide hydrolase (FAAH) and N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD). All of these component parts of the 'endocannabinoid system' have been demonstrated in rodent but not in human uteri. This study aimed to demonstrate the presence of the endocannabinoid system in the human uterus and catalogue its modulation. Immunohistochemical techniques were employed to localise and determine the distribution of immunoreactive CB1, CB2, FAAH, and NAPE-PLD in well-characterised menstrual cycle biopsy samples. Immunoreactive CB1 and CB2 were widely distributed throughout the uterine tissue. In the myometrium and endometrium, smooth muscle cells were immunoreactive, although the vascular smooth muscle cells in both tissues were more so. In the endometrium, CB1 and CB2 immunoreactivity was primarily restricted to the glandular epithelium and expression was unrelated to the phase of the cycle. FAAH immunoreactivity in the endometrium was highest in the mid-proliferative gland and mid-secretory stroma, whilst NAPE-PLD immunoreactivity was down-regulated in the secretory epithelial gland compared to the proliferative epithelial gland and unaffected in the stroma. These data indicate that elements of the 'endocannabinoid system' coexist in many cell types within the uterus and may provide insight into the sites of action of endogenous and exogenous cannabinoids during endometrial transformation.

Authors+Show Affiliations

Endocannabinoid Research Group, Reproductive Sciences Section, Department of Cancer Studies and Molecular Medicine, University of Leicester, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, P.O. Box 65, Leicester, Leicestershire, LE2 7LX, UK. aht3@le.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20369362

Citation

Taylor, Anthony H., et al. "Histomorphometric Evaluation of Cannabinoid Receptor and Anandamide Modulating Enzyme Expression in the Human Endometrium Through the Menstrual Cycle." Histochemistry and Cell Biology, vol. 133, no. 5, 2010, pp. 557-65.
Taylor AH, Abbas MS, Habiba MA, et al. Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochem Cell Biol. 2010;133(5):557-65.
Taylor, A. H., Abbas, M. S., Habiba, M. A., & Konje, J. C. (2010). Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. Histochemistry and Cell Biology, 133(5), 557-65. https://doi.org/10.1007/s00418-010-0695-9
Taylor AH, et al. Histomorphometric Evaluation of Cannabinoid Receptor and Anandamide Modulating Enzyme Expression in the Human Endometrium Through the Menstrual Cycle. Histochem Cell Biol. 2010;133(5):557-65. PubMed PMID: 20369362.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Histomorphometric evaluation of cannabinoid receptor and anandamide modulating enzyme expression in the human endometrium through the menstrual cycle. AU - Taylor,Anthony H, AU - Abbas,Muna S, AU - Habiba,Marwan A, AU - Konje,Justin C, Y1 - 2010/04/06/ PY - 2010/03/19/accepted PY - 2010/4/7/entrez PY - 2010/4/7/pubmed PY - 2010/9/21/medline SP - 557 EP - 65 JF - Histochemistry and cell biology JO - Histochem Cell Biol VL - 133 IS - 5 N2 - Plasma anandamide (AEA) levels fluctuate throughout the menstrual cycle and in early pregnancy in a pattern suggesting its involvement in implantation and early pregnancy maintenance through mechanisms that might involve its binding to cannabinoid receptors CB1 and CB2. Plasma AEA levels are maintained by the actions of the enzymes fatty acid amide hydrolase (FAAH) and N-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD). All of these component parts of the 'endocannabinoid system' have been demonstrated in rodent but not in human uteri. This study aimed to demonstrate the presence of the endocannabinoid system in the human uterus and catalogue its modulation. Immunohistochemical techniques were employed to localise and determine the distribution of immunoreactive CB1, CB2, FAAH, and NAPE-PLD in well-characterised menstrual cycle biopsy samples. Immunoreactive CB1 and CB2 were widely distributed throughout the uterine tissue. In the myometrium and endometrium, smooth muscle cells were immunoreactive, although the vascular smooth muscle cells in both tissues were more so. In the endometrium, CB1 and CB2 immunoreactivity was primarily restricted to the glandular epithelium and expression was unrelated to the phase of the cycle. FAAH immunoreactivity in the endometrium was highest in the mid-proliferative gland and mid-secretory stroma, whilst NAPE-PLD immunoreactivity was down-regulated in the secretory epithelial gland compared to the proliferative epithelial gland and unaffected in the stroma. These data indicate that elements of the 'endocannabinoid system' coexist in many cell types within the uterus and may provide insight into the sites of action of endogenous and exogenous cannabinoids during endometrial transformation. SN - 1432-119X UR - https://www.unboundmedicine.com/medline/citation/20369362/Histomorphometric_evaluation_of_cannabinoid_receptor_and_anandamide_modulating_enzyme_expression_in_the_human_endometrium_through_the_menstrual_cycle_ L2 - https://dx.doi.org/10.1007/s00418-010-0695-9 DB - PRIME DP - Unbound Medicine ER -